-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease (PD) is a common movement disorder among middle-aged and elderly people, which seriously affects the quality of life of patients
In response to the above problems, Professor Xiao Qin from the Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine gave a detailed explanation, hoping to help colleagues better grasp the clinical application of such drugs
video content
01:40
What is the status of levodopa in the latest PD treatment guidelines?
03:00
What is the origin of levodopa?
11:08
Which ratio is more suitable for levodopa and dopa decarboxylase inhibitor?
Benserazide or carbidopa, which dopa decarboxylase inhibitor is better?
23:56
Levodopa tablet, capsule and slow/controlled release, which dosage form is better?
28:25
What are the problems with traditional oral administration of levodopa?
32:27
How to optimize the use of levodopa?
37:53
What are the new drug delivery systems for levodopa?
Professor Xiao Qin
past review
☑ Professor Ma Jinghong | Interpretation of MDS-UPDRS Rating Scale
☑Professor Wang Han | Improve the quality of life of patients, correctly understand and use anti-PD drugs
